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Abstract
Astrocytes are extensively infected with HIV-1 in vivo and play a significant role in the development of HIV-1-associated
neurocognitive disorders. Despite their extensive infection, little is known about how astrocytes become infected, since they
lack cell surface CD4 expression. In the present study, we investigated the fate of HIV-1 upon infection of astrocytes.
Astrocytes were found to bind and harbor virus followed by biphasic decay, with HIV-1 detectable out to 72 hours. HIV-1
was observed to associate with CD81-lined vesicle structures. shRNA silencing of CD81 resulted in less cell-associated virus
but no loss of co-localization between HIV-1 and CD81. Astrocytes supported trans-infection of HIV-1 to T-cells without de
novo virus production, and the virus-containing compartment required 37uC to form, and was trypsin-resistant. The CD81
compartment observed herein, has been shown in other cell types to be a relatively protective compartment. Within
astrocytes, this compartment may be actively involved in virus entry and/or spread. The ability of astrocytes to transfer virus,
without de novo viral synthesis suggests they are capable of sequestering and protecting virus and thus, they could
potentially facilitate viral dissemination in the CNS.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) penetrates the
central nervous system (CNS) during acute infection [1].
Progression of HIV-1 disease within the CNS frequently causes
HIV-1 encephalitis (HIVE), HIV-associated dementia (HAD) or
less severe HIV-associated neurocognitive disorders (HAND) [2],
collectively affecting approximately 50% of the infected popula-
tion [3,4]. Within the CNS, HIV-1 productively infects resident
perivascular macrophages and microglia [5,6]. In contrast,
astrocytes undergo a restricted infection and produce little or no
virus [7–9]. Whilst astrocyte infection is restricted, their infection
leads to cellular dysfunction, resulting in altered gene expression,
loss of neuronal support, dysregulation of glutamate levels, and
altered blood-brain barrier integrity, all of which contribute to
HAND [2,8,10,11].
Infected astrocytes have been shown to express detectable levels
of early, multiply spliced HIV-1 gene products, including nef
[7,12,13]. Thus astrocyte infection is restricted whereby multiply
spliced HIV-1 mRNA may be selectively expressed without
completion of the virus replication cycle. Generally, it is believed
that astrocyte infection is controlled by two phases of restriction;
the acute phase and the dormant phase. During the acute phase,
replication in astrocytes results in low-level virus production,
which is controlled post-transcriptionally [14,15]. During the
dormant phase, there is restricted expression of viral transcripts
caused by low-level basal long terminal repeat (LTR) promoter
activity, which can be overcome with cytokine/chemical stimula-
tion [16,17]. The dormant phase is also likely to represent long-
term or latently infected cells, which are a current barrier to HIV-
1 eradication efforts. These two phases of the restricted state result
in initial suppression of virion production despite high level
mRNA synthesis, followed by eventual suppression of mRNA
transcription [8].
Several studies have examined the molecular mechanisms
involved in the restriction of HIV-1 production in astrocytes and
revealed that virus replication is restricted at multiple steps within
the virus lifecycle [7–9]. Astrocytes lack the CD4 receptor, which
is required for classical HIV-1 entry, and infection is thought to be
both CD4 and coreceptor independent [18,19]. Viral entry alone
is thought to be a significant bottleneck to fully productive
infection in astrocytes, as studies psuedotyping HIV with envelopes
from vesicular stomatitis virus (VSV) or murine leukemia virus
(MLV) achieved productive infection in astrocytes [20,21]. Other
studies have identified a cellular block in Rev function impairing
nucleocytoplasmic transport of Rev-dependent HIV-1 mRNA
[22,23], translational blocks despite high mRNA levels [14,15],
and a heightened protein kinase R (PKR)-mediated antiviral
response due to low levels of the PKR inhibitor, TAR-RNA
binding protein (TRBP) [8,24].
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Recovery of infectious virus from astrocytes has been demon-
strated using several approaches, including stimulation with
proinflammatory cytokines TNFa and IL1-b, or when co-cultured
with CD4+ cells [18,25,26]. These studies provide evidence that
given the appropriate stimuli in vivo, astrocytes have the potential
to act as a source of de novo HIV-1 within the CNS. The frequency
of astrocyte infection was previously believed to be 3% [5,7,27],
but more recent work in our laboratory using highly sensitive
techniques has indicated that this can be as high as 19% [28]. This
relatively high infection frequency coupled with the fact that
astrocytes are the most abundant cell type in the brain
(approximately 0.4 – 2.06 1012 cells), numerically suggests they
may represent a significant HIV-1 reservoir within the CNS
[7,29]. Additionally, the immune privileged nature of the CNS
and the reduced bioavailability [30] and activity of antiviral drugs
[31] add further complexity to efforts aimed at controlling and
preventing HIV-1 infection within the brain.
Here we aimed to characterise HIV-1 entry into astrocytes to
elucidate the entry pathway and the cellular compartments that
are involved in infection of astrocytes. Furthermore, we analysed
the ability of astrocytes to support trans-infection and identify the
compartment responsible for this form of viral dissemination. We
used novel immunofluorescence techniques to address these
questions using replication competent cell free HIV-1 with
relevant HIV-1 envelope glycoproteins. Consistent with previous
studies, we observed uptake of HIV-1 into vesicle compartments
[32,33] and we further show that these compartments are lined
with CD81. We also demonstrate that HIV-1 can be subsequently
released and transmitted to CD4+ T-cells without de novo synthesis,
suggesting astrocytes support trans-infection. The results of our
study suggest that the CD81 compartment can harbor and protect
HIV-1 whilst also acting as a vehicle to facilitate trans-infection of
neighboring cells. This pathway may potentially have a role in
HIV-1 dissemination within the brain.
Materials and Methods
Cell lines and primary cells
The SVG astrocyte cell line [34] was cultured in Minimum
Essential Medium (MEM) (Life Technologies, NY, USA) supple-
mented with 20% (vol/vol) heat-inactivated fetal calf serum (HI-
FCS), 100 mg/ml of penicillin and streptomycin, and 2 mM of
GlutaMAX (Life Technologies). The 293T cell line (ATCC) was
cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Life
Technologies) supplemented with 10% (vol/vol) HI-FCS, 100 mg/
ml of penicillin and streptomycin, and 2 mM of GlutaMAX. The
JLTRG cell line [35] was cultured in Roswell Park Memorial
Institute (RPMI) media (Life Technologies) supplemented with
10% (vol/vol) HI-FCS, 100 mg/ml of penicillin and streptomycin,
and 2 mM of GlutaMAX.
Production and quantitation of virus stocks
HIV-1 BaL was produced by transfection of 293T cells with the
provirus expression plasmid pBaL (HIV-1 subtype B molecular
clone). The supernatants containing virus were harvested 48 h
later, by ultracentrifugation over a 20% (wt/vol) sucrose cushion at
120,000 6 g for 1 h, quantified by p24 ELISA, and stored at -
80uC. EGFP content-labelled HIV-1 YU2ciGFP was produced by
co-transfection of 293T cells with the provirus expression plasmid
pYU2 (HIV-1 brain-derived molecular clone) and pTI3 at a ratio
of 15:1. pTI3 encodes for HIV-1 GAG-iGFP and was constructed
by replacing the EGFP open reading frame in peGFP-N1
(Clontech, CA, USA) with HIV iGFP [36,37]. Co-expression
leads to incorporation of HIV Gag-iGFP in trans and latter
cleavage of EGFP from HIV Gag during viral maturation. The
supernatants containing virus were harvested 48 h later, filtered
through 0.45 mm filters, and stored at 280uC.
HIV-1 p24 ELISA
Viral stocks and cell-associated virus was quantified using the
HIV-1 p24CA antigen capture assay kit (SAIC Frederick, AIDS
Vaccine Program, MD, USA), according to the manufacturer’s
protocol.
Virus half-life assays
SVG cells were seeded at 5,000 cells/well in 96-well plates. The
following day, SVG cells were pulsed with non-saturating amounts
(1.0 mg/ml p24, as determined via escalating dose loading and
saturation curve) of HIV-1 BaL for 2 h at 37uC. Cells were then
washed extensively and virus half-life was determined by HIV-1
p24 ELISA over a 72 h period.
trans-infection assays
We define trans-infection as the uptake and short-term transfer
of HIV-1 to permissive cells as outlined previously in HIV-1
exposed dendritic cells [38]. To observed transfer in the short-tem,
independent of de novo infection, we performed transfer experi-
ments as described previously. Briefly, SVG cells were loaded with
virus as detailed above, either at 4uC or 37uC [38]. After virus
loading, some samples were treated with 0.05% TrypLE (Life
Technologies) at 37uC for 10 mins to remove residual attached
surface accessible virus. Following washing, cells were co-cultured
with 10,000 cells/well of JLTRG cells overnight (16 h). The
following day the JLTRG cells were transferred to new plates and
cultured for a further 5 days before analysing EGFP expression via
FACS. Media treated SVG cells were included as a negative
control.
Immunofluorescence assays
To synchronise viral entry events, SVG cells were spinoculated
at 4uC for 1 h with the EGFP content-labelled HIV-1 YU2ciGFP,
followed by extensive washing and fixation with 4% paraformal-
dehyde (1 6 PBS) at 0, 15, 45 and 135 mins post-infection.
Figure 1. Astrocytes harbor short-term HIV-1 viral reservoirs.
Virus half-life assays were performed using HIV-1 BaL and the
immortalised human foetal astrocyte cell line, SVG. Cell-associated
HIV-1 p24 was quantified via ELISA over a time course from 0 to 72 h.
The curve of best fit is shown in black. The initial virus half-life of 1.2 h is
shown via a dotted dark gray line and the slower rate of 9.5 h is shown
via a dotted light gray line. Dot points and error bars denote the mean
and standard deviation, respectively. Data is representative of three
independent experiments.
doi:10.1371/journal.pone.0090620.g001
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Figure 2. HIV-1 colocalizes with CD81-lined vesicle compartments in astrocytes. (A) SVG astrocyte cells were infected with an EGFP
content-labelled HIV-1 YU2 virus (green) and samples were harvested at 135 mins post-infection. Cells were stained with the vesicle/endosomal
markers CD81, EEA1, CD63 or CD107b (red) and nuclei counterstained with DAPI (blue). Panels represent the individual fluorescent channels with the
HIV-1 Entry into Astrocytes
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Samples were immunofluorescently stained for vesicle and
endosomal markers using mouse anti-human antibodies specific
for CD81, EEA1, CD63, CD107b and isotype control (JS-81, 14/
EEA1, H5C6, H4B4, MOPC-21, clones respectively) (Becton
Dickinson, NJ, USA) at 1:200 and goat-anti mouse Alexa Fluor
555 (Life Technologies) at 1:400. Nuclei were counterstained using
Hoechst 33258 (Life Technologies). Samples were imaged on a
Zeiss Cell Observer microscope using an air objective (406, NA
0.75). IMARIS software (Bitplane, Zurich, Switzerland) was used
to analyse images and quantify co-localization using the Coloc
module as previously described [39]. Multiple fields of view and
three independent experiments were used to generate the data.
shRNA knockdown of CD81
SVG cells were seeded at 30,000 cells/well in a 12-well plate.
The following day the media was replaced with full media
supplemented with 0.5 mg/ml polybrene and cells were transduced
with 20 ml of shRNA lentiviral particles specific for either CD81 or
negative scrambled shRNA (Santa Cruz Biotechnology, TX,
USA). 24 h post-transduction the media was changed and 48 h
post-transduction, puromycin was introduced in escalating doses.
A week later cells were cultured in 2 mg/ml puromycin and cells
were analysed via FACS for expression of CD81 using a FITC-
conjugated mouse anti-human antibody specific for CD81 (Becton
Dickinson).
Results
Astrocytes harbor short-term HIV-1 viral reservoirs
We first tested the ability of astrocytes to bind and harbor HIV-
1 over a time course to determine if they were capable of
supporting the establishment of short-term viral reservoirs. Non-
saturating amounts of HIV-1 BaL were used to load astrocytes,
followed by extensive washing and analysis of the cell-associated
HIV-1 p24. Astrocytes demonstrated a biphasic decay of virus,
with an initial half-life of 1.2 hours followed by a slower rate of
9.5 hours (Figure 1). Cell associated virus was detectable out to
72 hours, potentially suggesting they are capable of supporting the
establishment of short- to mid-term viral reservoirs.
HIV-1 associates with CD81-lined compartments in
astrocytes
To determine the cellular compartment involved in sequestering
HIV-1 in astrocytes, we next performed immunofluorescence
studies. Astrocytes were infected with an EGFP content-labelled
HIV-1 and were immunofluorescently stained for vesicle and
endosomal markers including CD81, EEA1, CD63 and CD107b.
HIV-1 was found to colocalize with the vesicle marker CD81
(Figure 2A), with colocalization quantified using IMARIS image
software (Figure 2B). This colocalization increased overtime and
was most pronounced at the 135-minute time point. In contrast,
the endosomal and lysosomal markers EEA1, CD63 and CD107b
had minimal or no colocalization with HIV-1. These findings
suggest that HIV-1 may use CD81-lined vesicles as a potential
short-term reservoir compartment. Additionally, this compartment
may also be responsible as the entry site of HIV-1 into astrocytes.
Reducing CD81 expression did not alter the association
between HIV-1 and CD81-lined compartments
To determine whether CD81 was directly involved in recruiting
HIV-1 to CD81-lined compartments, we next performed shRNA
studies targeting CD81. Astrocytes were treated with lentiviral
particles encoding for shRNA specific for CD81 (SVG-lowCD81)
or a non-specific scrambled shRNA control (SVG-scramble).
CD81 levels were significantly silenced by 77% (P,0.0001) using
shRNA specific for CD81 (Figure 3A). In contrast, the scrambled
shRNA did not alter CD81 levels. We next repeated the virus
loading and immunofluorescence studies done previously using
these two new cell lines. The SVG-lowCD81 cells maintained their
association between CD81-lined compartments and HIV-1,
despite reduced CD81 levels (Figure 3B). The amount of CD81-
HIV-1 colocalization was significantly higher (P,0.0001) in the
SVG-lowCD81 cells compared to SVG-scramble cells (Figure 3C).
These results suggest that CD81 acts as a marker of the vesicle
compartment in which HIV-1 localizes, but may not have a direct
role in recruitment of virus to this compartment.
Astrocytes support trans-infection of HIV-1
To test the hypothesis that astrocytes can support trans-infection
we performed virus loading and transfer experiments to T-cells.
We define trans-infection as the uptake and short-term transfer of
HIV-1 to permissive cells in the absence of de novo infection.
Astrocytes were loaded with non-saturating amounts of HIV-1 at
37uC alone, 37uC followed by mild trypsin treatment, or 4uC.
Media treated cells were included as a negative control. Following
virus loading and extensive washing, cells were co-cultured with
the JLTRG reporter T-cell line. Transfer of virus from astrocytes
to T-cells results in their infection and subsequent EGFP
expression was measured using FACS. Compared to media
treated astrocytes, cells loaded with virus at 37uC or 37uC +
trypsin resulted in a significant induction of EGFP expression in T-
cells (P=0.0005, P=0.001, respectively) (Figure 4). In contrast,
astrocytes loaded with virus at 4uC resulted in no significant
increase in EGFP in T-cells compared to media treated astrocytes.
These results suggest that astrocytes are capable of supporting
trans-infection of HIV-1 with subsequent transfer to T-cells. In
addition, the virus-containing compartment required 37uC to form
and was insensitive to trypsin treatment suggesting these structures
were internal to the cell and may assist in protecting HIV-1.
Discussion
The aim of this study was to identify the entry pathway of HIV-
1 into astrocytes and to determine whether astrocytes were capable
of supporting trans-infection. In astrocytes we demonstrated that
cell-associated HIV-1 undergoes biphasic decay and could be
harbored for long periods of time. We identified that HIV-1 was
taken up into vesicle compartments lined with CD81 and that
alteration of CD81 levels did not influence the colocalization of
HIV-1 and CD81. Finally, we revealed that astrocytes are capable
of supporting trans-infection. Together these findings shed new
light on the entry process of HIV-1 into astrocytes and suggest
they may also play an active role in viral dissemination within the
CNS.
overlay (OL) on the far right. Scale bars are 10 mm. Images are representative of multiple fields of view and three independent experiments. (B)
Quantification of colocalization of vesicle/endosomal markers with HIV-1 using IMARIS software. Bar graphs and error bars represent the mean and
standard deviation, respectively. Data are a compilation of multiple fields of view and three independent experiments.
doi:10.1371/journal.pone.0090620.g002
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Figure 3. CD81-HIV-1 association is maintained when CD81 expression is reduced. (A) CD81 expression levels of the parental SVG cell line,
SVG-scramble (cells treated with shRNA-scramble) and SVG-lowCD81 (cells treated with shRNA-CD81) cells as determined via FACS analysis. The data
are expressed as mean values and error bars represent standard deviation. (B) SVG-scramble and SVG-CD81 cells were infected with an EGFP content-
labelled HIV-1 YU2 virus (green) and samples were harvested at 135 mins post-infection. Cells were stained with the vesicle marker CD81 (red). Panels
HIV-1 Entry into Astrocytes
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The viral kinetics of HIV-1 infection of astrocytes suggests that
these cells may harbor virus for long periods of time. During the
initial phase of infection the virus likely sequesters in multiple
compartments, each with its own rate of decay, as evidenced by
the observed biphasic half-life of the virus. The bulk of the virus
associates with a rapidly decaying compartment with a half-life of
1.2 hours while the remaining virus associates with a slower
decaying compartment with a half-life of 9.5 hours. This later
compartment likely comprises CD81-lined vesicles, which have
been shown elsewhere to be relatively protective structures in other
cell types [40,41], and is supported by our data with an increased
virus half-life. Previous reports identified that HIV-1 has a very
rapid decay, with a half-life in the order or minutes to hours (0.4 –
1.8 hours)[27,42]. Together, these findings suggest that astrocytes
may play a role in sequestering virus, resulting in prolonged virus
viability and potentiating increased infection and spread within the
CNS.
Immunofluorescence analysis of astrocytes after brief exposure
to HIV-1 demonstrated predominant association with CD81
stained structures. CD81 and HIV-1 were concentrated into
compact, apparently intracellular structures, with virions accumu-
lating into several distinct foci throughout the cell. CD81-HIV-1
colocalization was also observed to increase overtime, suggesting
either HIV-1 actively migrates to CD81 vesicles for protection, or
that virus in other compartments is preferentially degraded while
virus in CD81 vesicles is protected. The association of HIV-1 with
CD81-positive compartments has been reported previously in
dendritic cells [40,41,43] and macrophages [44], but here we show
for the first time that these structures also form in astrocytes. Of
particular interest, these same reports have shown that this
compartment is involved in facilitating trans-infection of T-cells via
dendritic cells. Much earlier work from our group identified that
HIV-1 associates in vesicle-like structures but the exact compart-
ment remained elusive [32]. Clarke et al., also suggested these
structures were most likely formed via macropinocytosis or
phagocytosis [45] and would be consistent with the involvement
of the mannose receptor [33]. We conclude that these vesicle-like
structures can be identified using CD81, as shown here and
elsewhere, and they play a crucial role in HIV-1 entry into
astrocytes, whilst also supporting trans-infection of neighboring
cells.
We also observed a weaker association between HIV-1 and the
early endosome marker, EEA1. This may represent multiple entry
routes of the virus into astrocytes, which is again supported by the
biphasic virus half-life within astrocytes. We chose our various
vesicle, endosome and lysosome markers to cover a wide spectrum
of different cellular structures involved in endocytosis and cellular
uptake. Of these, CD81 is a marker for vesicles, and represents the
earliest form for cellular uptake. Therefore it is not unexpected
that we found the strongest association with this compartment.
Future work is required to determine the role each of these
compartments plays in entry and trans-infection. It is also unclear
whether these are transient events with subsequent progression
into late endosome/lysosome causing degradation of their
contents.
The silencing of CD81 in astrocytes resulted in a significant
reduction in CD81 expressed on the cell surface. However,
immunofluorescence studies performed with these same cells did
not adversely affect the association between HIV-1 and CD81. We
also observed a reduction in the amount of overall virus associated
with the CD81 depleted cells. When colocalization was compared
to the parental cells we observed an increased reliance on CD81-
lined compartments in the CD81 depleted cells. Because CD81
expression was not completely eliminated, it is unclear whether
CD81 itself has a direct role in recruiting HIV-1 into this
compartment. Reducing CD81 levels could result in two distinct
outcomes: 1) it may affect the stability of the vesicle structures
resulting in fewer forming or 2) it may simply deplete CD81
content from these vesicles with no affect on total vesicle numbers.
Future work will explore these two scenarios using CD81-mutant
cell lines, and immunofluorescence of associated vesicle markers.
Together these results suggest that CD81 serves as a marker of the
cellular compartment with which HIV-1 associates in astrocytes.
Trans-infection experiments revealed that astrocytes are indeed
capable of facilitating transfer of virus to neighboring cells in the
absence of de novo infection. To our knowledge, this is the first
demonstration that astrocytes possess this capability in vitro. While
trans-infection has been definitively shown in dendritic cells
[36,40,41], this is the first report within CNS cells, and provides
new insights into the potential of astrocytes to influence viral
dissemination within the brain.
In addition to the trans-infection studies, experiments performed
at 4uC or in the presence of trypsin revealed important insights.
Firstly, physiologically relevant temperatures were required for the
formation of the compartment involved in trans-infection. This
suggests that the uptake of virus is an active process and likely
involves enzymes and reactions that can only function at 37uC.
Secondly, the compartment harboring virus does not involve virus
adhered to the outside of the cell, as trypsin treatment would
effectively remove this virus. Additionally, the data also suggests
represent the individual fluorescent channels with the overlay (OL) on the far right. Scale bars are 10 mm. Images are representative of multiple fields
of view and three independent experiments. (C) Quantification of colocalization of CD81 with HIV-1 using IMARIS software. The data are expressed as
mean values and error bars represent standard deviation. Data are a compilation of multiple fields of view and three independent experiments. P
values were calculated using a parametric unpaired t test; ****, P , 0.0001.
doi:10.1371/journal.pone.0090620.g003
Figure 4. Astrocytes are capable of trans-infection. FACS analysis
of EGFP expression in JLTRG cells following co-culture with SVG cells
loaded with virus under different conditions (37uC, 37uC followed by
trypsin treatment, or 4uC). Media treated cells were included as a
negative control for background fluorescence in the JLTRG cells. The
data are expressed as mean values and error bars represent standard
deviation. Data are a compilation of three independent experiments. P
values were calculated using a parametric unpaired t test; ***,
P= 0.0005; **, P= 0.001.
doi:10.1371/journal.pone.0090620.g004
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that the compartment may be intracellular with no access to the
extracellular space, rendering it trypsin-resistant. Cavrois et al.,
recently performed a study in dendritic cells to demonstrate that
trans-infection occurred primarily by surface-accessible HIV-1 and
suggested that internalized HIV does not play a role in trans-
infection [46]. This finding somewhat contradicts that of our own,
but may be explained due to the different model and cell type
used. More recently, Yu et al. concluded that Cavrois et al. findings
were limited and successfully demonstrated that the vast majority
of HIV-1 involved in trans-infection is derived from internalized
non-endosomal compartments that remain contiguous with the
plasma membrane [41]. While these findings are more corrobo-
ratory with our own data, the trypsin-resistant nature of our
compartment may represent an astrocyte-specific structure.
Several groups have demonstrated that infectious HIV-1 can be
recovered from astrocytes up to 5 months post-infection [47,48].
The ability of astrocytes to harbor and transmit virus without
replication may represent an important mechanism by which
HIV-1 can evade the immune system and antiretroviral drugs.
Additionally, this non-replicative mode of HIV-1 persistence and
transmission may potentially be involved in HIV-1 entry and
spread within the CNS. Furthermore, this novel virus/astrocyte
interaction may also represent an additional way in which HIV-1
causes astrocyte dysfunction in the absence of viral replication.
The interplay between the virus and intracellular vesicles could
alter the normal astrocyte vesicle sorting events required for
recycling of neurotransmitters and export of neurotropic factors.
Further elucidation of non-replicative astrocyte infection is
required to comprehensively understand HIV-1 entry, spread
and persistence within the CNS.
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